Company Information
MEDIPOST Co., Ltd. was established in Seoul, Korea in 2000 and listed on KOSDAQ in 2005 (KOSDAQ ticker: 078160) with current market cap USD $400M. MEDIPOST has 240 employees and half of them are engaged in R&D. CELLTREE® is MEDIPOST’s umbilical cord blood bank that has successfully commercialized the world’s first allogeneic stem cell drug. Based on world-class stem cell technology, CELLTREE® has boasted a unique and thorough management for extraction, storage, and transplantation of the umbilical cord blood-derived stem cells. Blood from the umbilical cord of newborn infants, is rich in both the Hematopoietic Stem Cells (HSCs) which create blood components, and Mesenchymal Stem Cells (MSCs) which grow into tissues such as cartilage, bones and muscle. This is why umbilical cord blood is widely recognized as a precious life resource which can regenerate many different types of damaged adult tissues and restore their function. MEDIPOST’s Research & Development is also focused on providing novel therapeutics for patients using allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cells for Osteoarthritis (OA), Broncho-pulmonary Dysplasia (BPD) and Alzheimer's Disease (AD). MEDIPOST's flagship product CARTISTEM® for OA has been approved by the regulatory agency, the Ministry of Food and Drug Safety (MFDS) in Korea as an allogeneic cell therapy product in 2012 and to date over 17,000 patients have been treated on market. Post Market Surveillance (PMS) with 600 patients has been successfully completed in Korea and in the last 7 years and no safety issues have been reported in any of the patients both clinical trial and commercial. CARTISTEM® has also successfully completed Phase 1/2 trial in the U.S. PNEUMOSTEM® for the prevention of Bronchopulmonary Dysplasia (BPD) with Orphan Drug Designation in Korea, U.S. and E.U., is currently under Phase 2 clinical trial in Korean and Phase 1/2 clinical trial has been completed in the U.S.
